Barrow Neurological Institute

06/02/2026

June is .

Myasthenia gravis is a rare disease that causes fluctuating fatigue and weakness in voluntary muscles, like those in the face, neck, throat, diaphragm, and limbs. It happens when the body’s immune system creates antibodies that disrupt communication between nerves and muscles, making it difficult for muscles to contract.

Symptoms may include drooping eyelids, double vision, difficulty speaking or swallowing, and trouble lifting objects. Although there is no cure for , treatments can help relieve symptoms and, in some cases, lead to remission.

To learn more about myasthenia gravis, and how our in the Gregory W. Fulton ALS and Center can help, visit https://bar.rw/myastheniagravis.

(🎨: Barrow Publications)

06/01/2026

The North Carolina Society has announced Juan S. Uribe, MD, FAANS, Chief of the Division of Spinal Disorders at , as the invited guest and keynote speaker for its 2026 Annual Meeting. The meeting will be held from June 19 to 21, 2026 at the Washington Duke Inn & Golf Club.

Dr. Uribe will give the following presentations:

Dinner and Networking Special Talk: "Going Viral for the Wrong Reasons: Social Media Lessons for "
📆: Friday, June 19
⏰: 7:30 to 9:30 p.m. (EDT)

Keynote Address: "MIS Lateral: Nuances and Complication Avoidance"
📆: Saturday, June 20
⏰: 8:05 to 9:05 a.m. (EDT)

To view the full agenda and sign up for the meeting, visit https://bar.rw/ncspine2026.

(🎨: Barrow Publications)

06/01/2026

Congratulations to Sarah Sternbach, MD, and her collaborators in the Neurocritical Care Program at on receiving the Natus Resident/Fellow Award for at the American Association of Neurological Surgeons Annual Meeting ( )!

AANS presents this award to the best neurocritical care abstract submitted by a resident or fellow. Dr. Sternbach performed this research with pharmacy specialist Tyler Haller, PharmD, BCCCP, and acute care nurse practitioner Diane McLaughlin, DNP, AGACNP-BC, CCRN, FCCM, FNCS, MBA. She credits them with conceiving the project and welcoming her participation.

The team performed a retrospective cohort study of patients with acute brain injuries. These patients had dangerously high blood pressure despite receiving maximal doses of nicardipine and thus were switched from the first-line medication to another agent, known as clevidipine.

Drs. Sternbach, Haller, and McLaughlin found that nearly 85% of these patients achieved blood pressure control within one hour of starting clevidipine and that side effects were rare. Their study suggests that clevidipine is a safe and an effective rescue option for one of the most challenging problems in neurocritically ill patients.

05/29/2026

In observance of ( ), members of the Ivy Brain Tumor Center team at joined azfamily 3TV CBS 5 to discuss the topic.

Kelly Braun, MD, a at Barrow, shared how her own journey with a inspired her career choice. She also explained why brain tumors can be difficult to treat and how the is working to address these challenges.

Shwetal Mehta, PhD, the Ina Levine Chair for at Barrow and the deputy director of the Ivy Center, discussed how the Ivy Center's Phase 0 work and why philanthropy is key to making progress in brain tumor treatments.

Watch the segments at https://bar.rw/btam2026.

05/28/2026

Congratulations to Barrow President and CEO Michael T. Lawton, MD, on recently being named as one of the "Five Neurosurgeons to Know" by Becker's Spine Review.

In the list, Becker's highlighted five who "stand out for their clinical expertise, scientific contributions, and leadership in driving breakthroughs in research, surgery, and academic medicine."

The article recognized Dr. Lawton's expertise in the treatment of blood vessel malformations in the nervous system as well as his innovative contributions to research and global education.

View the list at https://bar.rw/5neurosurgeons.

05/28/2026

We're thrilled to introduce our incoming summer !

Selected from a highly competitive pool of applicants, these 30 students represent 13 universities across the United States, Mexico, and Brazil. Of the three international interns, two are funded by the Franke Education Center at Barrow.

Starting June 4, these bright minds will spend 10 weeks learning from mentors in our translational laboratories, clinical spaces, and other areas of .

“We are really excited to welcome this year’s cohort to Barrow,” said Rita Sattler, PhD, MSc, David and Weezie Reese Chair for Neurodegeneration Research and director of the Summer Program. “Every year, these students bring a level of curiosity, energy, and fresh perspective that pushes all of us, and we are looking forward to seeing what they accomplish over the summer. It’s always impressive how quickly they become part of the community and contribute in meaningful ways to the work happening across the Institute.”

Visit https://bar.rw/undergrads2026 to learn more about the interns and the Program.

05/27/2026

At ’s Gregory W. Fulton & Neuromuscular Disease Center, we are committed to our patients and families. We stand alongside you every day—through care, connection, and progress. We’re here for you.

Learn more at BarrowNeuro.org/ALS.

05/26/2026

05/23/2026

Congratulations to the research team at the whose poster presentation received third place in the clinical research category at the Arizona Medical Association Annual Meeting earlier this month.

The poster focused on a nationwide study of United States Medicare beneficiaries that explored the associations between urban and rural residence, drinking water sources, and .

This work was presented by Vishal Harnoor, a rising fourth-year student at Creighton University School of Medicine/Creighton University Health Sciences - Phoenix.

Learn more about the Barrow Neuro Analytics Center at https://bar.rw/bnac.

05/22/2026

May is .

is an inherited disease that causes nerve cells in the brain to deteriorate over time. This typically results in uncontrolled movements, cognitive losses, and behavioral changes.

About 41,000 Americans are living with Huntington's disease, and every child of a parent with Huntington's disease has as 50/50 chance of inheriting the affected gene.

While there is no known treatment to halt, slow, or reverse the progression of Huntington's, there are medications and therapies that can help manage symptoms. At Huntington's Disease Society of America Centers of Excellence like the at , patients benefit from a variety of specialists who are highly experienced in supporting families affected by Huntington's.

Learn more: https://bar.rw/huntingtons